Evotec Investor Day Presentation Deck

Less data available: HTS Ongoing investment in screening collection 74 66 evotec 49 41 33 25 16 8 0 PAGE 80 Row Count 0.00 0.10 0.20 0.30 0.40 0.50 0.60 0.70 0.80 0.90 1.00 QEDw mo3 (16 bins) Evotec Screening Collection Known Drugs 49000 44300 39400 34500 29500 24600 -19700 15000 -10000 5000 0 Balancing speed, cost & probability of technical success Early Hit ID: Extensive capabilities in small molecules Highest quality chemical start points • Best value Desirable feature QED 3 D shape Lip E LE N=N ara Molecular term Composite property clog D MW Value 0.91 chiral 1.1 314 GPCR homology model directed screen Protein//DNA endonuclease SBDD/LBDD screens Protein//Protein inter-action SBDD/LBDD screens ¹) Wu etaCBB 201 More data available: Virtual Screening Skp2 Chan of Cill 2013 Field Pharmacophore guided LBDD Protein//RNA transferase SBDD/LBDD screens Pharmacophore guided LBDD excluded volumes F8: Aro (aternativel F1: Cat&Don Få: Ara P3: Hyd F7: Aco FG: Don F5: Acc F4: Aro F2: Aro

View entire presentation